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Expression of fibroblast growth factor 1 is lower in breast cancer than in
the normal human breast
GS Bansal, C Yiangou, RC Coope, JJ Gomm, YA Luqmani*, RC Coombes and CL Johnston
Department ofMedical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Summary We have measured the amount of fibroblast growth factor (FGF-1) mRNA and protein in
primary breast cancers and non-malignant breast tissue and have found greatly reduced levels in breast cancer
compared with non-malignant tissue. A total of 116 breast cancers and 37 biopsies taken from non-malignant
breast were compared for FGF-1 mRNA expression using reverse transcriptase-polymerase chain reaction
(RT-PCR) and significantly lower levels were found in the cancer tissues (P<0.001). These findings were
confirmed at the protein level where four out of five breast cancers contained no detectable FGF-1 and a fifth
cancer had a low level of FGF-1 compared with three samples from reduction mammoplasties. Similar results
were obtained from breast cell lines in which 80% of cancer cell lines had very low levels of FGF-1, whereas
all non-malignant breast cell lines contained higher levels of FGF-1. Immunohistochemical analysis indicated
that FGF-1 was present in the luminal epithelial cells of the non-malignant breast but was absent from cancer
cells. The decreased levels of FGF-l in breast cancer may indicate that stimulation of cancer cells is resulting
in down-regulation of FGF-1 expression or may implicate FGF-1 as a differentiation factor rather than a
growth factor at its physiological concentration in the breast.
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The fibroblast growth factors (FGFs) form a family of nine
identified growth regulatory proteins that share 35-50%
overall homology and induce proliferation and differentiation
of a wide range of cells of epithelial, mesodermal and
neuroectodermal origin (Gospodarowicz et al., 1987; Burgess
and Maciag, 1989; Klagsbrun, 1990; Goldfarb, 1990). All,
except FGF-1 and 2, are synthesised with an N-terminal
hydrophobic signal sequence, enabling the classical mech-
anism of secretion from cells (Abraham et al., 1986; Jaye et
al., 1986). Release of FGF-1 and 2 may occur through
leakage from damaged cells or from viable cells through a
novel mechanism (Mignatti et al., 1992; Cao and Pettersson,
1993). FGF-1 and 2 have both been reported to show nuclear
as well as cytoplasmic localisation (Cao and Pettersson, 1993;
Vijayan et al., 1993).
The response of cells to FGFs is mediated through forma-
tion of a ternary complex of growth factor, proteoglycan and
high-affinity receptor (Yayon et al., 1991; Klagsbrun and
Baird 1991; Rapraeger et al., 1991; Ornitz et al., 1992; Kan et
al., 1993). A family of tyrosine kinase receptors encoded by
at least four separate genes [FGF receptor (R)-l-4] have
recently been identified (Lee et al., 1989; Dionne et al., 1990;
Kornbluth et al., 1988; Keegan et al., 1991; Partanen et al.,
1991; Mansukhani et al., 1992). The complexity ofthis family
is enhanced by an array of spliced variants resulting in
receptors with altered ligand binding and signalling charac-
teristics (Hou et al., 1991; Johnson et al., 1991; Jaye et al.,
1992; Miki et al., 1992; Yayon et al., 1992).
We have previously shown that FGF-1 and 2 are both
present in human breast tissue (Gomm et al., 1991; Luqmani
et al., 1992; Smith et al., 1994). FGF-2 has been localised to
the myoepithelial cells of normal breast by immuno-
cytochemistry but could not be detected in either normal or
malignant epithelial cells (Gomm et al., 1991). Bioassayable
FGF-1 was present in conditioned medium from breast
cancer biopsies (Smith et al., 1994). Receptors for FGF-1
and 2 are found in breast cancer cells and we have detected
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both FGFR-1 and FGFR-2 mRNA in normal and neoplastic
breast tissues as well as several breast cell lines by RT-PCR
(Luqmani et al., 1992). Recent studies show that in a large
panel of breast cancer cell lines, all receptors are expressed to
some degree in most lines but that FGFR-4 predominates
(Ron et al., 1993; McLeskey et al., 1994). A 2- to 4 fold
amplification of the FGFR-4 gene has been reported in 10%
of 30 primary breast tumours suggesting that FGFR-4 may
have a role in breast tumorigenesis (Jaakkola et al., 1993).
In an extensive immunohistochemical survey of normal
tissues Hughes and Hall (1993) found FGF-1 to be present in
almost all tissues, including liver, skin, kidney, ureter and
vasculature. FGF-1 immunoreactivity was found in bladder
tumour tissue; very little was found in normal bladder cells
(Barritauld et al., 1991). More recently, studies have been
carried out that implicate autocrine and intracrine mech-
anisms in some carcinoma cells since FGF-1 and its receptor
are co-expressed and FGF-1 stimulated proliferation (Chao
et al., 1993).
As a result of these findings, we have carried out a more
extensive study in breast tissues, in which we have compared
the FGF-1 content in normal and neoplastic breast samples
and correlated our findings in cancers with clinical features.
These results have been compared with expression in a varie-
ty of breast cell lines. We also present preliminary data on
the localisation of FGF-1 in cryostat sections.
Materials and methods
Materials
Reverse transcriptase was from Gibco-BRL (Paisley, UK),
Taq polymerase from Penninsula Laboratories (UK), DNA
polymerase Klenow fragment and dNTPs from Pharmacia
(Uppsala, Sweden). RNAzol was from Biogenesis (Bourn-
emouth, UK). Alpha [32P]dCTP (3000 Ci mmol-') and
Hybond N+ membranes and Hyperfilm were from Amer-
sham (UK). Nitrocellulose membranes were from Schleicher
& Schull (UK). Anti-FGF-I rabbit polyclonal sera used for
Western blotting was from British Biotechnology. Recom-
binant FGF-1 16 kDa protein was a gift from Ludwig Ins-
titute for Cancer Research, Stockholm, Sweden. All other
reagents were obtained from Sigma (Poole, UK) unless
otherwise indicated and were of the highest available grade.Oligonucleotides
Oligonucleotide primers were synthesised on a Cyclone Plus
DNA Synthesizer (Milligan Bioresearch, MA, USA). The
FGF-1 primers used for the PCR were: for FGF-I 5'-
GATGGCACAGTGGATGGGAC-3' and 5'-AAGCCCGT-
CGGTGTCCATGG-3' and for actin, 5'-CATCTCTTGCTC-
GAAGAAGTCCA-3' and 5'-ATCATGTTTGAGACCTTC-
AA-3'.
Cell lines
Thirteen human mammary cell lines were used in this study:
three breast cell lines of non-malignant origin, HBL100
(myoepithelial), HBRSV1.6.1 (epithelial) and MCF1Oa (epi-
thelial), and 11 derived from cancer tissue; T47D, ZR75-1,
SKBR11 1, MDA-MB361, MDA-MB415, MDA-MB453,
MDA-MB157, BT20, PMC42 and MCF7. The human rhab-
domyosarcoma cell line A204 was used as a positive control,
as it is known to express FGF-1. A further nine non-breast
cell lines (DAUDI, JAR, HEPG2, Hela, Myoblast, KATO
III, GEE, SMN and PAP) were also analysed for com-
parison. (For origin of these lines, see Khan et al., 1994.) All
but three of these cell lines were cultured in RPM1-1640
medium buffered with 25 mM Hepes and supplemented with
10% fetal calf serum, 100 units ml' penicillin, 100jLg ml-'
streptomycin and 2 mM L-glutamine. The A204 and SKBR-
111 cells were grown in McCoy's 5A medium with the same
supplements as above and the MCF1Oa cells in a medium
containing equal quantities of Dulbecco's modified Eagle
medium and Ham's nutrient mixture F-12 buffered with
15 mM Hepes with the following supplements: 10 gml1l
insulin, 1.4 nM hydrocortisone, 100 ng ml' cholera enter-
otoxin, 20 ng ml epidermal growth factor, 5% horse serum,
2mM glutamine, 100unitsml-' penicillin and 100 gml1'
streptomycin. Cells were harvested at about 80% confluency
for both RNA extraction and protein analysis.
Tissues
Breast tissue obtained at surgery was snap frozen and stored
in liquid nitrogen. We collected cancer tissue from 116
patients whose details are given in Table I, showing these to
be a typically representative cohort of breast cancer patients
with 35% of patients being pre/perimenopausal and 56%
having oestrogen receptor-positive carcinomas. Breast tissue
Table I Clinical details of patients in this study
Parameter No ofpatients (%)
Total 116
Age range (years) 29-89
Median age 57
Menopausal status
Pre/peri 36 35
Post 68 65
Unknown 12
Nodal status
Positive 37 41
Negative 53 59
Unknown 26
Clinical stage
Tl/2 73 83
T3/4 15 17
Unknown 28
Pathological stage
TI/2 63 71
T3/4 26 29
Unknown 27
Histological type
Invasive ductal 93 93
Invasive lobular 7 7
Unknown 16
Oestrogen receptor
Positive 27 56
Negative 21 44
Unknown 68
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adjacent to carcinoma or from benign conditions his-
tologically confirmed to be non-malignant was also collected
and is referred to as normal. Breast organoids were prepared
from normal breast tissues obtained from reduction mamm-
oplasties, essentially by the method described by Stampfer et
al. (1980).
Immunohistochemistry
Immunocytochemistry was carried out using a mouse mono-
clonal antibody raised in collaboration with J Walters
(Brookes University, Oxford, UK) against a 38 amino acid
peptide sequence of FGF-1 corresponding to amino acids
60-98. The full characterisation of this antibody is the sub-
ject of another report (R Coope et al., in preparation).
Briefly, cryostat sections (7-10gM) of breast tissue were
incubated with the FGF-1 antibody overnight at 4°C. Sec-
tions were then incubated with biotinylated anti-mouse IgG
followed by an avidin-biotin peroxidase complex. Staining
was visualised using 0.05% 3-diaminobenzidine and counter-
stained with Gill's haematoxylin.
SDS-PAGE and Western blotting
Monolayers of cultured cells grown in petri dishes were lysed
in standard SDS-PAGE sample buffer. Frozen tissue samples
were pulverised to a fine powder and also dissolved in lysis
buffer. All samples were sonicated for 30 s using a sonicator
at maximum output. Aliquots of 50 yg of protein (Bradford,
1976) were electrophoresed through a 15% polyacrylamide
gel and the separated proteins were transferred onto
nitrocellulose membranes by overnight blotting at 4°C. After
blocking with 3% milk powder in phosphate-buffered saline
(PBS) supplemented with 0.1% Tween 20 (PBS-T) for 1 h at
20°C, the membranes were incubated with a commercially
available rabbit polyclonal anti-FGF-I antibody (British
Biotechnology) for 1 h. The blots were then incubated, after
washing, for 1 h with an anti-rabbit IgG conjugated to
horseradish peroxidase. After five washes with PBS-T, bands
were visualised using the ECL method (Amersham, UK), as
described in the manufacturer's protocol.
Determination ofFGF-I mRNA by RT-PCR amplication
Cellular RNA was extracted from pulverised frozen tissues
using the guanidinum isothiocyanate method (Chirgwin et
al., 1979) and from the cell lines by the modified RNAzol
procedure (Chomczynski and Saachi, 1987). Reverse trans-
cription and PCR amplification was performed as described
previously (Luqmani et al., 1992). Briefly, 2 Lg of RNA was
reverse transcribed using random primers and cDNA was
amplified using 1 unit of Taq polymerase in 100pl containing
200 ng ofeach of the FGF-l and actin primers, by sequential
cycles of denaturation at 94°C for 1 min, annealing at 45°C
for 1 min and extension at 72°C for 1 min (extended to
10min for the final cycle). An aliquot was removed after 18
cycles for estimation of actin product and the reaction con-
tinued for a further ten cycles for estimation of FGF-1.
Aliquots (10 pl) of the 28-cycle and 18-cycle PCR products
were electrophoresed on separate 1% agarose gels and alkali
blotted overnight onto Hybond N+ membrane (Luqmani et
al., 1992).
Hybridisation was carried out as described by Church and
Gilbert (1984). We initially used plasmids containing FGF-1
or actin cDNA for hybridisations to verify identity and size
ofPCR products. As single bands were seen, we subsequently
used PCR products (made using plasmid template) random
primer labelled (Feinberg and Vogelstein 1983) with [32P]-
dCTP (5.108-109 c.p.m.fig-'; 106 c.p.m. ml-'). Washed blots
were exposed to hyperfilm for several hours and band inten-
sities were quantified by densitometry.
The value for FGF-1 was normalised by dividing the signal
for FGF-1 by that for actin. Separate blots were normalised
to each other by using an arbitrary sample, which was pres-
ent on every run and every blot, to correct for differencesFGF-1 in human breast
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between experiments caused by gel loading, running, transfer,
hybridisation and times of autoradiographic exposure.
Results
Expression ofFGF-I mRNA in breast tissues
PCR conditions were optimised as described before (Luq-
mani et al., 1992) to ensure that amplification was within the
linear phase. Eighteen cycles of PCR were selected for
estimation of actin levels and 28 cycles for FGF-1 (data not
shown). All 37 normal and 116 neoplastic breast tissues
examined produced the expected FGF-1 PCR product of
135 bp. In each case a single band corresponding to 319 bp
was also seen for actin. However, the levels of amplified
FGF-1 were significantly higher (P = 0.001) in the normal
tissues: the median value for FGF-1/actin ratio in normal
tissues was 23.3 (range 2.4-489) compared with 5.7 (range
0.29-157) in breast cancer tissues (Figure 1).
Correlation ofFGF-J mRNA expression in cancers with
clinicalparameters
The details of the patients studied are summarised in Table I.
Our results were analysed with respect to five prognostic
parameters: T stage, pathological size, nodal involvement,
oestrogen receptor status and menstrual status (see Table II).
No relationship was seen between FGF-l mRNA levels and
any of these prognostic parameters. Although clinical T stag-
ing appeared to correlate with FGF-l mRNA levels
(P<0.05), this was not confirmed when we examined the
relationship with pathological tumour size. There was no
relationship between FGF-1 mRNA content and time to
relapse or overall survival in the patients studied (P = 0.817
and 0.297 respectively).
observed three bands corresponding to 14, 16 and 18 kDa
peptides (Figure 2). Since the preparation of organoids
involves trypsin digestion, we believe that these three bands
are probably produced by tryptic digestion of the expected
18kDa band.
The presence of one cancer containing FGF-1 agrees with
the mRNA data since some cancers maintained high levels of
FGF-1 mRNA. The range of mRNA levels for normal tissue
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Figure 1 Scattergram showing relative amounts of FGF-1 PCR
product standardised to the amount of actin (simultaneously
amplified) obtained from either cancer or normal biopsies as
described in Materials and methods. The median values of the
two groups (5.7 and 23.3 respectively) were significantly different
(P = 0.001).
Western blot analysis ofbreast tissues
Cell lysates were made from several breast cancers and nor-
mal reduction mammoplasty specimens and Western blot
analysis was used to compare expression of FGF-1. A
monoclonal antibody against FGF-l (British Biotechnology),
which has previously been shown to bind to FGF-I but not
to FGF-2 (manufacturer's information and our own results),
was used. We were unable to obtain sufficient protein from
the normal samples owing to their high fat content. To
overcome this problem we used organoid preparations of the
reduction mammoplasties, which yield principally the cellular
component of the breast. No signals corresponding to FGF-I
were seen in four of the five cancers examined but a weak
band corresponding to an 18 kDa product was visible in one
case (Figure 2, lane 5). For all three organoid samples we
Mol. wt
18
1A
2 3 4 5 6 7 8 9
21
14 14
kDa
Figure 2 Western blot analysis of FGF-1 protein in breast tiss-
ues. Extracts were subjected to SDS-PAGE as described in
Materials and methods, transferred to nitrocellulose membrane,
incubated with anti-FGF-1 antibody (British Biotechnology) and
then with peroxidase-conjugated anti-rabbit IgG followed by
visualisation using the Amersham ECL kit. Lane 1 contained
10 ng of recombinant of 16 kDa FGF-l protein. Lanes 2-4
contain extracts of normal breast organoid tissue. Lanes 5-9
contain cancer biopsy samples.
Table II Relationship between FGF-I levels and clinical parameters
FGF-I/actin ratio
n Median Range P-valuee
Oestrogen receptor
Negative 21 6.0 0.65-33 0.24
Positive 27 8.5 0.63-157
Clinical stage
Tl/T2 73 5.0 0.63-157 0.02
T3/T4 15 10.5 1.9-44
Pathological stage
TI/T2 63 5.2 1.1-157 0.89
T3/T4 26 6.4 0.63-44
Node status
Positive 53 6.7 1.5-157 0.97
Negative 37 5.2 0.65-44
Menopausal status
Pre 36 5.0 1.1 -44 0.8
Post 68 6.0 0.63-157
aCalculated using Mann-Whitney U-testb
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Figure 3 Immunoperoxidase staining of breast tissue. (a) A sec-
tion of carcinoma in which reactivity to an anti-FGFl antibody
is seen only in the normal cells adjacent to the tumour; the cancer
cells are unstained. (b) A negative control in which the primary
antibody was non-immune mouse immunoglobulin. (c) Strong
cytoplasmic FGF-1 immunoreactivity in the epithelial cells of
ducts in a section of normal breast tissue. Magnification x 150 (a,
b) and x 300 (c).
appears to be wider than the range of FGF-1 seen in the
Western blot, in which high levels of FGF-1 were seen in all
samples. This could reflect the smaller number of samples
analysed in the Western blotting experiment.
Immunocytochemical localisation
A mouse monoclonal antibody raised against amino acids
60-98 of FGF-I was used to determine the localisation of
FGF-I in the breast. This antibody has been shown to be
specific since it binds to FGF-1 but not to FGF-2 in Western
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Figure 4 Histograms showing the relative amounts of FGF-1
PCR product standardised to actin in breast (a) and non-breast
(b) cell lines.
blot experiments (R Coope et al., manuscript in preparation).
In cryostat sections, FGF-1 immunostaining was only
detected in normal breast epithelial cells. Figure 3a demon-
strates FGF-1 staining of the epithelium of a normal duct
adjacent to non-staining malignant epithelial cells on a breast
cancer section. Figure 3b is the negative control of the same
tissue treated with non-immune mouse IgG. At a higher
magnification, Figure 3c shows intense FGF-1 staining
associated with the cytoplasm and membrane of normal
epithelial cells. No nuclear localisation was seen. We believe
the epithelial cell staining to be specific since the peptide to
which the antibody was raised was able to block the staining
(R Coope et al., manuscript in preparation).
Expression ofFGF-I mRNA andprotein in breast cell lines
We examined mRNA from 14 breast cell lines. FGF-1 prod-
uct was obtained from all of these lines but levels were
generally higher in the three non-malignant cell lines.
(HBRSVI.6.1, HBL100 and MCF1Oa) as compared with the
majority of the cancer derived lines; two of the cancer cell
lines (MDA-MB-361 and SKBR111), however, also had
levels similar to the non-malignant lines (Figure 4a). We also
found FGF-1 product in all of the ten non-mammary cell
lines examined, with the A204 cells having the highest levels
(similar to those found in the breast tissues) (Figure 4b).
Overall, the values normalised to actin showed that expres-
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sion in the cell lines was considerably lower than that seen in
tissue samples.
FGF-1 protein was detectable by immunoblotting in the
A204 cells (data not shown) and in the three non-malignant
breast cell lines tested (HBrSVI,6.1, HBL100 and MCF10a).
A band corresponding to the expected 18 kDa FGF-I protein
was seen in each case. No FGF-1 protein was detected in
four of the five breast cancer cell lines tested but a band
similar to that seen in the normal cell lines was observed with
MDA-MB-231 cancer cells (Figure 5). Immunostaining of
these cell lines gave similar results (data not shown) with
staining seen only in the non-malignant lines.
In summary, the non-malignant cell lines of both
myoepithelial and epithelial origin contain both the FGF-1
mRNA and the translated protein whereas the changes
involved in carcinogenesis have led to a reduction in the
expression of FGF-1 in 80% of the malignant cell lines
tested.
Discussion
In this study, we have compared the expression of FGF-1
mRNA and protein in malignant and non-malignant breast
using 153 tissue samples and 14 breast derived cell lines.
Using all methods we noted a decrease in the expression of
FGF-I in breast cancer. Semiquantitative PCR allowed the
detection of FGF-I mRNA in all the tissue samples, however
the levels seen in cancers were significantly lower than those
seen in non-malignant tissues. This finding is in marked
contrast to a study of FGF-1 expression in pancreatic cancer
in which FGF-1 mRNA was found to be overexpressed in
cancer with expression levels correlating with tumour stage
(Yamanaka et al., 1993).
We have confirmed our results by using Western blotting
to monitor the level of FGF-l protein present in breast
tissues. The same pattern of expression is seen, with non-
malignant cell lines and tissue samples containing higher
levels of FGF-1 than cancer cell lines and tissue samples.
FGF-I would be expected to be translated as a single form of
18 kDa and this single band is seen in all benign cell lines
and tissues analysed (Burgess and Maciag, 1989; Cao and
Pettersson, 1993). Additional bands of 14 kDa and 16 kDa
are seen in reduction mammoplasty tissue. This process was
required because the higher fat content of non-malignant
tissue compared with breast tumours made it difficult to
achieve lysates of normal tissue with protein concentrations
similar to those of the cancer sample lysates without using
organoid preparation as a way of enriching for cells.
The cellular localisation of FGF-I was studied on cryostat
sections using immunohistochemistry. FGF-I protein was
found predominantly in the luminal epithelial cells of normal
ducts. This is in agreement with a previous study showing
strong anti-FGF-l immunoreactivity in the glandular epi-
thelium (Hughes and Hall, 1993). Again, a large decrease in
FGF-1 expression was seen in breast cancer, with no staining
apparent in breast cancer cells. Thus luminal epithelial cells
normally express FGF-1 and transformation of these cells
results in loss of expression of FGF-1.
The study of FGF-1 expression in breast-derived cell lines
showed that non-malignant cell lines of both epithelial and
myoepithelial phenotypes expressed FGF-1. We observe
staining only on the luminal epithelial cells of cryostat sec-
tions and two theories could explain this difference. One
possibility is that myoepithelial cells do not express FGF-l
under normal conditions in the breast, however changes involved in growing myoepithelial cells in tissue culture con-
ditions might induce expression of FGF-1. Alternatively,
both cell types may express FGF-l in the breast but FGF-l
becomes associated predominantly with the luminal epithelial
cells in vivo. In situ hybridization experiments would be
required to assess the situation in vivo. Anandappa et al.
(1994) have reported decreases in FGF-I mRNA expression
in the malignant breast using Northern blot experiments.
This less sensitive technique did not allow detection ofFGF-l
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Figure 5 Western blot analysis of FGF-1 protein in cell lines.
Recombinant FGF-1 (10ng) (lane 1) and extracts from HBL-100
(lane 2), MCF1Oa (lane 3), MDA-MB-231 (lane 4), MCF7 (lane
5), T47D (lane 6), ZR75-1 (lane 7), SKBR111 (lane 8) and
HBRSV1.6.1 (lane 9) cell lines were run on a 7.5% SDS-PAGE,
transferred to nitrocellulose and probed with an anti-FGF-I
antibody (British Biotechnology), followed by anti-rabbit IgG
-peroxidase conjugate and developed using ECL reagents.
mRNA in epithelial and myoepithelial cells and stromal
elements were suggested as the source of FGF-1. Our studies
identify non-malignant epithelial cells as the expressors of
FGF-1.
FGF-1 is present in normal breast ducts and we and others
have detected receptors for FGF-1 on both epithelial and
myoepithelial cells (Luqmani et al., 1992; Jacquemier et al.,
1994; McLeskey et al., 1994). This raises the possibility that
FGF-1 has roles in autocrine or paracrine control of
epithelial and myoepithelial cells in the normal duct. The role
of FGF-1 in the normal duct is unclear since, although
FGF-1 can stimulate mitogenesis in some breast cancer cell
lines (Briozzo et al., 1991; Johnston et al., 1995), there have
been reports of FGF-1 treatment leading to a decreased rate
of growth (McLeskey et al., 1994). FGF stimulation of PC12
cells leads to differentiation rather than proliferation and it is
possible that the function of FGF-1 is to maintain the diff-
erentiated state of the duct rather than cause cell prolifera-
tion (Kremer et al., 1991). Our results show a dramatic
decrease in the amount of both FGF-1 mRNA and protein
in breast cancer compared with non-malignant biopsy sam-
ples. This may lead to the loss of any regulatory function
performed in the breast by FGF-1. If FGF-1 has a role in
maintaining the differentiated state of the breast duct, then
loss of FGF-1 expression may contribute to the malignant
phenotype.
An apparently contradictory situation occurs for FGF
receptors. Experiments have shown an increase in the
number of receptors in breast cancer compared with normal
epithelial cells. Gene amplification of the FGFR-4 gene has
been found in 10% of breast cancers (Jaakkola et al., 1993).
Increased expression of FGFR-1 has been found in 15% of
breast tumours and a panel of breast cancer cell lines show
amplification of either FGFR-1 or FGFR-4 in several cell
lines (Jacquemier et al., 1994; McLeskey et al., 1994). Both of
these receptors would bind FGF-1 with high affinity, how-
ever in the absence of FGF-1 in breast cancer it is possible
that these overexpressed receptors will be activated by an
alternative ligand such as FGF-4 or FGF-6, although neither
of these has been detected in the breast (Vainikka et al.,
1992). It has recently been reported that FGF receptors also
interact with adhesion molecules, with such interactions
leading to receptor activation and Ca2" influx (Williams et
al., 1994). It is possible that alternative interactions such as
these are responsible for stimulating the overexpressed FGF
receptors in breast cancer.
The decrease in FGF-1 expression in breast cancer cells is
striking. It is a frequent change occurring in carcinogenesis
since at least 80% of breast cancers contain no detectable
FGF-I by Western blot analysis and immunohistochemistry.
Further investigation will be required to assess the functional
effect of the decrease in this growth factor. The presence of
FGF-l and its receptors in the normal breast suggests a role
for this factor in the maintenance of the normal duct. The
decrease in FGF-1 in cancer would be expected to perturb
A
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the epithelial cells and could be influential in the progression
of carcinogenesis.
Abbreviations
FGF-1 and -2, acidic and basic fibroblast growth factor; FGFR,
fibroblast growth factor receptor; RT, reverse transcriptase; PCR,
polymerase chain reaction.
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Note added in proof
Since writing this paper, a more extensive immunocytochemical
study of FGF-1 expression in frozen sections of human breast has
been carried out. We continue to see a decrease in FAF-1 expression
in malignant epithelial cells, however FGF-1 staining is seen in the
stroma surrounding malignant epithelial cells, whereas no stromal
staining is seen in non-malignant samples. This is discussed fully in a
further paper by R Coope et al., submitted to Cancer Research.
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